Vital Stats: Biothera's Wellmune WGP 1,3-1,6 beta glucan
Study claim: Wellmune WGP may prevent upper respiratory tract infections, and improve overall health and mood, following a competitive marathon.
Published: Talbott S and Talbott J. Effect of beta 1, 3/1, 6 glucan on upper respiratory tract infection symptoms and mood state in marathon athletes. Sports Sci Med 2009;8:509-15.
Abstract: This was a placebo-controlled, double-blind study designed to evaluate the effect of a commercially available dietary supplement on upper-respiratory tract symptoms (URTI) and mood state. Seventy-five marathon runners (35 men, 40 women) ranging in age from 18-53 years, mean age: 36 ± 9, self-administered placebo, 250mg or 500mg of beta 1,3/1,6 glucan (commercial name Wellmune WGP) daily during the four week post-marathon trial period following the 2007 Carlsbad Marathon. Subjects filled out the profile of mood state (POMS) assessment and a questionnaire-style health log measuring health status and URTI symptoms after two- and four-week treatment administrations. During the course of the four-week study, subjects in the treatment groups (250mg and 500mg beta-glucan per day) reported significantly fewer URTI symptoms; better overall health; decreased confusion, fatigue, tension and anger; and increased vigor based on the POMS survey compared to placebo.
Potential applications: Derived from a proprietary strain of Baker's yeast, Wellmune WGP activates white blood cells (neutrophils) to more quickly find and kill foreign challenges. Designed for foods, beverages and dietary supplements, it is kosher, halal, nonallergenic and GMO free.
Vital stats: Nutrition 21's Chromax chromium picolinate
Study claim: Chromium picolinate decreases oxidative stress and inflammation, and it does not increase the risk for kidney damage.
Published: Mozaffari MS, et al. Effects of chromium picolinate on glycemic control and kidney of the obese Zucker rat. Nutr Metab 2009;6:51.
Abstract: Chromium picolinate (Cr(pic)3) is advocated as adjuvant therapy for impaired glycaemic control, despite DNA damage concerns. Potential toxicity of Cr(pic)3 should be greater for the kidney, which accumulates chromium. Therefore, the study tested the hypothesis that, despite improved glycaemic status, Cr(pic)3 treatment of obese Zucker rats (OZRs) at higher-than-human doses exacerbates renal abnormalities associated with dysglycemia. Male OZRs were treated with diets lacking or containing 5mg/kg and 10mg/kg of Cr(pic)3, for 20 weeks; lean Zucker rats (LZRs) served as controls. Glycaemic and renal effects of Cr(pic)3 were determined in the context of indices of oxidative stress and inflammation.
The OZRs displayed increased fasting plasma glucose and insulin in association with enlarged pancreatic islets exhibiting collagen and periodic acid Schiff-positive deposits compared to LZRs; Cr(pic)3 treatment did not affect these parameters. The OZRs, irrespective of Cr(pic)3, excreted more albumin than the LZRs. Also, other indices of renal function or histopathology were not affected by Cr(pic)3 treatment. Urinary excretion of 8-hydroxydeoxy guanosine (8-OHdG), an index of oxidative DNA damage, was greater in the OZRs than the LZRs; dietary Cr(pic)3 treatment attenuated 8-OHdG excretion. However, immunostaining of the kidney for 8-OHdG revealed a similar staining pattern and intensity, despite significant renal accumulation of Cr(pic)3-treated groups. Finally, increased renal nitrotyrosine and cyclo-oxygenase-2 levels and urinary excretion of monocyte chemo attractant protein-1 of OZRs were partially reversed by Cr(pic)3 treatment.
Potential applications: Appropriate for weight management, sports nutrition and metabolic health supplements, and functional foods and beverages.
+1 914 701 4549